Ca-AKG (Calcium Alpha-Ketoglutarate): Evidence Review

Medically reviewed by Dr Zeeshan Afzal (MBBS), Medical Officer, Welzo. Last updated: July 2026.

Calcium alpha-ketoglutarate (Ca-AKG) is one of the few longevity supplements with a genuinely striking animal result behind it: middle-aged mice fed the compound lived longer and, more importantly, spent a smaller proportion of their lives frail. That single 2020 study from the Buck Institute for Research on Aging turned an obscure Krebs cycle intermediate into a mainstream supplement category almost overnight.

But an impressive mouse study is not the same thing as human evidence. This calcium alpha-ketoglutarate review works through what has actually been measured — in worms, flies, mice and people — separates the well-supported claims from the marketing, and sets out what a sensible, evidence-led approach to Ca-AKG looks like in 2026.

If you are building a broader routine, start with our complete guide to longevity supplements, our detailed breakdown of NMN benefits, side effects and dosage, and our range of NMN supplements — including NMN Pro 1000, the most commonly used starting point for people beginning a NAD⁺-focused protocol.

Quick Verdict: Is Ca-AKG Worth Taking?

• Strongest evidence: reduced frailty and extended median lifespan in mice; robust mechanistic biology in the TCA cycle and epigenetic regulation.
• Weakest evidence: human lifespan, human healthspan, and "biological age reversal" — currently supported only by uncontrolled or observational data.
• Best-supported human finding: a reduction in a bone resorption marker in postmenopausal women with osteopenia, from a genuine randomised double-blind trial.
• Typical dose used commercially: 1,000–3,000 mg Ca-AKG daily, usually as a sustained- or delayed-release format.
• Main practical caution: Ca-AKG is roughly one-fifth elemental calcium by weight, so higher doses contribute meaningfully to your total daily calcium intake.
• Verdict: a reasonable, low-risk experimental addition for people already covering the basics — not a proven intervention, and not a priority ahead of exercise, sleep and diet.

Table of Contents

• What Is Calcium Alpha-Ketoglutarate?
• Why AKG Became a Longevity Target
• How Ca-AKG Works: Mechanisms of Action
• The Animal Evidence
• The Human Evidence
• Evidence Grading: Claim by Claim
• Ca-AKG Dosage: What the Research Actually Used
• Safety, Side Effects and Who Should Avoid It
• Ca-AKG vs Other Longevity Supplements
• How to Choose a Ca-AKG Supplement in the UK
• Should You Take Ca-AKG? A Practical Verdict
• Frequently Asked Questions
• References

What Is Calcium Alpha-Ketoglutarate?

Alpha-ketoglutarate (AKG, also written α-ketoglutarate or 2-oxoglutarate) is not an exotic botanical or a novel drug. It is a molecule your mitochondria produce continuously as part of the tricarboxylic acid (TCA) cycle — the central energy-generating pathway in almost every cell in your body. Chemically it is a five-carbon dicarboxylic acid with the formula C₅H₆O₅.

Chemical structure of alpha-ketoglutaric acid. Image: Wikimedia Commons, public domain.

Calcium alpha-ketoglutarate is simply AKG bound to calcium as a salt. The free acid is hygroscopic, unstable and unpleasant to take; binding it to a mineral produces a stable, water-soluble white powder that can be capsulated. Calcium is the mineral partner used in essentially all longevity-branded AKG products, and it is the exact form used in the pivotal mouse lifespan study.

Structure of calcium alpha-ketoglutarate (Ca-AKG). Image: Wikimedia Commons, public domain.

Ca-AKG vs AKG vs Other Salt Forms

The AKG you find on shelves comes in several forms, and they are not interchangeable in terms of the research behind them.

If you are buying on the basis of the longevity research, Ca-AKG is the form to buy. Arginine AKG products sold for the gym are a different category of product answering a different question.

How Much Calcium Is in a Ca-AKG Dose?

This matters more than most product pages admit. Calcium accounts for roughly 20% of the weight of calcium alpha-ketoglutarate. In practical terms:

The NHS advises that adults aged 19 and over need 700 mg of calcium a day, and that supplemental intakes above 1,500 mg a day can cause stomach pain and diarrhoea. If you already take a calcium supplement, a bone-health formula, or a fortified protein powder, a high Ca-AKG dose needs to be counted in your total.

Why AKG Became a Longevity Target

The Age-Related Decline in Circulating AKG

The interest in supplementing a metabolite your body already makes comes from a specific observation: circulating AKG appears to fall substantially with age. A widely cited 2008 review by Harrison and Pierzynowski reported that human plasma AKG concentrations decline roughly ten-fold between the ages of 40 and 80. The Buck Institute team referenced exactly this observation when justifying their mouse experiment, noting that AKG is not meaningfully available from the diet — which makes direct supplementation the only practical way to restore levels.

That single figure has been repeated so often in supplement marketing that it deserves a caveat. It comes from an older review rather than a large modern cohort with standardised metabolomics, and plasma levels of a rapidly-turning-over intracellular metabolite are an imperfect proxy for what is happening inside cells. The direction of the finding is consistent across the literature; the precise magnitude should be treated as approximate.

Where Ca-AKG Sits Among the Hallmarks of Ageing

AKG is unusual among supplement ingredients in that it plausibly touches several of the classical hallmarks of ageing simultaneously: mitochondrial dysfunction, epigenetic alteration, deregulated nutrient sensing, altered intercellular communication (inflammation), and loss of proteostasis. That breadth is part of the appeal — and part of the reason claims about it have run so far ahead of the data.

How Ca-AKG Works: Mechanisms of Action

1. Central Node in the TCA Cycle

AKG sits at the junction of carbon and nitrogen metabolism. In the TCA cycle, isocitrate is converted to alpha-ketoglutarate by isocitrate dehydrogenase, and AKG is then converted to succinyl-CoA by the alpha-ketoglutarate dehydrogenase complex — the rate-limiting step of the cycle.

Isocitrate to alpha-ketoglutarate, catalysed by isocitrate dehydrogenase. Image: Wikimedia Commons, CC BY-SA 4.0.

Alpha-ketoglutarate to succinyl-CoA — the rate-limiting step of the TCA cycle. Image: Wikimedia Commons, CC BY-SA 4.0.

AKG is also the direct carbon skeleton for glutamate and, downstream, glutamine and proline. Proline availability is one reason AKG has been studied for collagen synthesis and bone.

2. Cofactor for Epigenetic "Eraser" Enzymes

This is arguably the most interesting mechanism for ageing. AKG is an obligatory co-substrate for the family of 2-oxoglutarate-dependent dioxygenases. That family includes the TET enzymes, which demethylate DNA, and the JmjC-domain histone demethylases, which strip methyl marks from histones. Both are central to how the epigenome drifts with age.

This provides a biologically coherent — though still unproven in humans — link between AKG availability and the DNA methylation patterns that biological age clocks measure. It is the reason essentially every human AKG study to date has used epigenetic age as its primary outcome. If you want the wider context on that measurement, see our guide to how to lower your biological age.

3. Nutrient Sensing: mTOR, AMPK and ATP Synthase

The 2014 Nature paper by Chin and colleagues that started the field found that AKG extended lifespan in the nematode C. elegans by binding to and inhibiting ATP synthase, with downstream inhibition of TOR signalling. A 2019 study in fruit flies reported lifespan extension via mTOR inhibition and AMPK activation — the same nutrient-sensing axis targeted by caloric restriction, rapamycin and metformin. Suppressed mTOR signalling is also the trigger for autophagy.

Importantly, the mouse study could not reproduce this. After three months of Ca-AKG feeding, the Buck Institute team detected no decrease in mTORC1 signalling in the mouse tissues they examined. The mechanism that works in worms does not appear to be the mechanism that worked in mice — a genuinely important caveat that supplement marketing tends to omit.

4. Suppression of Chronic Inflammation

The mechanism the mouse study did support was immunological. Aged control mice showed the expected rise across most of 24 measured inflammatory cytokines; Ca-AKG-fed animals were largely protected from that rise. Splenic T cells from treated animals produced significantly more interleukin-10 (IL-10), a potent anti-inflammatory cytokine. In cell culture, AKG did not prevent cells from becoming senescent but did dampen their senescence-associated secretory phenotype — reducing IL-1β, IL-6, CCL2 and MMP3.

Notably, this effect was sex-specific: the cytokine and IL-10 changes appeared in female mice and not in males.

5. Collagen and Connective Tissue Support

AKG is a required co-substrate for prolyl 4-hydroxylase, the enzyme that hydroxylates proline residues during collagen biosynthesis. That is the mechanistic basis for AKG's long research history in bone, skin and connective tissue — and it overlaps with the rationale for other ingredients covered in our supplements for skin ageing guide.

The Animal Evidence

Nematodes (C. elegans)

Chin and colleagues (Nature, 2014) reported that AKG extended adult lifespan in C. elegans by around 50%, and identified ATP synthase subunit β as the direct binding target. The effect required a functional TOR pathway and was not additive with dietary restriction, suggesting they act through overlapping mechanisms.

Fruit Flies (Drosophila)

Su and colleagues (Aging, 2019) reported AKG-induced lifespan extension in fruit flies, attributed to mTOR inhibition and AMPK activation.

Mice: The Pivotal 2020 Study

This is the study that built the category, and it is worth understanding in detail rather than through headline numbers.

Asadi Shahmirzadi and colleagues at the Buck Institute fed C57BL/6 mice a diet containing 2% (w/w) calcium alpha-ketoglutarate, beginning at 18 months of age — the rough equivalent of starting an intervention in a human in late middle age. They ran two independent cohorts totalling 183 animals and assessed health using a validated 31-item frailty index scored blind, repeated roughly every eight weeks.

The headline conclusion was not really about lifespan. It was compression of morbidity: the reduction in frailty was proportionally larger than the increase in lifespan, meaning treated animals spent a smaller fraction of their lives in poor health. Specific improvements included coat condition, fur colour retention, gait, kyphosis and dermatitis, with increased locomotor activity confirmed objectively in metabolic cages.

What the Mouse Study Did Not Show

Three findings deserve as much attention as the positive ones:

• Male survival was not significantly improved in either cohort. The lifespan effect was a female effect.
• Treated mice did not perform better on a treadmill exhaustion test, and echocardiography showed no cardiac functional improvement. Ca-AKG is not an endurance aid on this evidence — see our guide to supplements for endurance athletes for what does have data.
• The control diet lacked calcium. The authors flagged this themselves as a limitation. It is unlikely that calcium alone extends mouse lifespan, but it was not formally ruled out in this design.

The Dose Problem

Here is the number that rarely appears in marketing. A 2% w/w dietary concentration, for a mouse eating roughly 4 g of food per day and weighing around 30 g, works out at approximately 2,600 mg/kg body weight per day. Applying the standard FDA allometric conversion for mouse-to-human equivalent dose (divide by 12.3) gives roughly 210 mg/kg/day — around 15 grams per day for a 70 kg adult.

Commercial Ca-AKG products typically supply 1–3 g per day. Allometric scaling is a crude tool and is not a prediction of the dose a human would need for the same effect, but the gap is large enough that anyone claiming a 1 g capsule reproduces the mouse result is overstating the case considerably.

The Human Evidence

This is where a calcium alpha-ketoglutarate review has to be honest. The human dataset is small, mostly uncontrolled, and dominated by a single outcome measure.

The Rejuvant Retrospective Analysis (2021)

Demidenko and colleagues published a retrospective analysis in Aging of 42 people who had taken Rejuvant — a commercial formulation combining approximately 1,000 mg of a sustained-release Ca-AKG with sex-specific vitamins — for an average of seven months. Using the TruAge DNA methylation test, the authors reported an average reduction in biological age of roughly eight years.

The number is eye-catching. The design is not. This was a retrospective analysis of self-selected customers with no placebo group, no randomisation and no control arm. Several authors had commercial ties to the product. DNA methylation clocks also carry meaningful test-retest variability, and regression to the mean is a real concern when people who test "old" are more likely to start an intervention and then retest. The finding is a hypothesis worth testing, not a demonstrated effect.

The Aging Cell Cohort Study (2026)

The most recent and largest human dataset comes from Pabis and colleagues, published in Aging Cell in 2026. The team analysed 4,260 "health enthusiasts" who purchased saliva-based epigenetic age tests between 2020 and 2025 and completed detailed supplement and lifestyle questionnaires, using a 9-CpG clock with a mean absolute error of 5.4 years.

Across 84 commonly used supplements, delayed-release alpha-ketoglutarate showed the strongest association with a lower biological age — reported at approximately 1.8 years lower age residual — and was described as the only supplement retaining statistical significance after adjustment for confounders. Supplement users overall had a lower epigenetic age than non-users, and the researchers found no evidence that taking multiple supplements together was harmful, which is relevant if you are wondering whether you can take supplements together.

This is a much stronger dataset than the 2021 retrospective — larger, independently conducted, and comparing AKG against 84 alternatives on a level playing field. It remains cross-sectional and observational. People who buy premium delayed-release longevity supplements differ from those who do not in income, health literacy, exercise habits and diet, and no statistical adjustment fully removes that. Association is not causation, and the authors themselves frame the result as a reason to run controlled trials.

Bone Health: The One Proper Randomised Trial

The best-designed human study of Ca-AKG is also the oldest, and it was not a longevity study. Filip and colleagues (2007) ran a randomised, parallel-group, double-blind, six-month trial in 76 postmenopausal women with osteopenia. One group received AKG calcium salt providing 6 g of AKG plus 1.68 g of calcium daily; the control group received the same calcium alone.

The critical detail is the design: because the control group received identical calcium, this trial isolated the effect of the AKG itself. The bone turnover marker moved; actual bone density did not move significantly relative to control over six months. It is meaningful supporting evidence for a real biological effect in humans — and it used 6 g of AKG per day, two to six times the typical commercial dose.

Older Clinical Nutrition and Dialysis Research

Ca-AKG has a longer clinical history than most longevity ingredients. It has been studied as a phosphate binder in haemodialysis patients, where it performed comparably to calcium carbonate for phosphate control and was investigated for correcting secondary hyperparathyroidism, and it has been used in enteral nutrition research for amino acid metabolism. This history is mainly useful as safety reassurance rather than as evidence of anti-ageing effects. Some dialysis patients discontinued because of gastrointestinal side effects, particularly those with pre-existing stomach problems.

The Trial That Will Actually Answer the Question: ABLE

The ABLE trial (Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults) is the study to watch. Run by Sandalova, Kennedy, Maier and colleagues at the National University of Singapore, it is a double-blind, placebo-controlled randomised trial of 1 g sustained-release Ca-AKG versus placebo for six months, with three months of follow-up, in 120 generally healthy adults aged 40–60 who have a DNA methylation age higher than their chronological age. The primary outcome is change in DNA methylation age.

A recruitment feasibility paper was published in Experimental Gerontology in 2025, confirming that recruiting biologically older but generally healthy middle-aged adults is workable. A separate randomised, double-blind, placebo-controlled trial in adults aged 45–75 has also been registered on ClinicalTrials.gov (NCT07114536).

Until these trials report, there is no randomised placebo-controlled evidence that Ca-AKG slows human ageing. Anyone telling you otherwise is describing the mouse study.

Evidence Grading: Claim by Claim

For a broader look at which popular ingredients survive this kind of scrutiny, see our analysis of longevity supplements that don't work and our examination of whether resveratrol works.

Ca-AKG Dosage: What the Research Actually Used

Doses Used in Human Studies

A Sensible Practical Range

Most people using Ca-AKG for general longevity purposes take 1,000–2,000 mg per day. That range sits at or slightly above the dose being tested in the only ongoing randomised trial, and keeps the elemental calcium contribution to roughly 200–400 mg — comfortably within normal dietary territory for most adults.

Going to 3,000 mg or beyond adds meaningful calcium load without any human evidence that the higher dose does more. If you are new to this category entirely, our guide on how to start longevity supplements covers sequencing and how to avoid changing five things at once.

Timing and Food

There is no human trial establishing an optimal time of day for Ca-AKG. Two practical considerations apply. First, AKG is acidic and some people find it easier on the stomach with food. Second, calcium competes for absorption with iron, zinc and magnesium, so if you take those separately it is sensible to space them a couple of hours apart. Our broader supplement timing chart and our article on which supplements to take on an empty stomach cover the general principles.

Delayed and Sustained Release: Does It Matter?

This is one of the few formulation questions with any supporting signal. Free AKG has poor oral bioavailability — first-pass metabolism in the gut wall consumes much of an enteral dose before it reaches circulation, which was demonstrated in pig studies decades ago. Both the ABLE trial and the products associated with the positive human observational data use sustained- or delayed-release Ca-AKG rather than immediate-release powder.

That is not proof that delayed release is superior, but if you are choosing between products and the research you are relying on used delayed release, matching the format is a defensible decision.

How Long Before You Notice Anything?

Realistically, nothing. Ca-AKG has no acute perceptible effect. The human studies ran for six to seven months and measured molecular markers, not subjective wellbeing. If a Ca-AKG product makes you feel noticeably different within days, that is worth investigating rather than celebrating. See how long supplements take to work for realistic timelines across this category.

Safety, Side Effects and Who Should Avoid It

The Overall Safety Picture

Alpha-ketoglutarate has a reassuring safety record. It is an endogenous human metabolite, it holds GRAS (Generally Recognized as Safe) status in the United States, and it has been used in clinical research in dialysis, trauma and post-surgical nutrition settings without notable safety signals. The mouse study detected no significant adverse effects at a dietary concentration far above any human supplemental dose.

Reported Side Effects

• Gastrointestinal upset — the most commonly reported issue. Stomach discomfort, nausea or loose stools, more likely at higher doses and in people with pre-existing gastric problems. In the dialysis literature, discontinuations clustered in patients with prior stomach issues.
• Calcium-related effects — constipation, bloating, and at high total intakes the stomach pain and diarrhoea the NHS specifically warns about above 1,500 mg supplemental calcium daily.
• Sour or acidic taste — relevant for powders rather than capsules.

Who Should Not Take Ca-AKG Without Medical Advice

• Anyone with a history of kidney stones, particularly calcium oxalate stones — additional supplemental calcium warrants a conversation with your GP.
• People with chronic kidney disease or on dialysis — calcium and phosphate handling is tightly managed in this group and must not be altered independently.
• People with hypercalcaemia, hyperparathyroidism or sarcoidosis, or anyone already taking prescribed calcium or high-dose vitamin D.
• Anyone taking thiazide diuretics, digoxin, levothyroxine, tetracycline or quinolone antibiotics, or bisphosphonates — calcium interacts with all of these, mainly by impairing absorption or altering calcium handling. Timing separation or avoidance may be needed.
• Pregnant or breastfeeding women — no data; avoid.
• Under 18s — no data; avoid.
• People with active cancer — AKG interacts with metabolic and epigenetic pathways relevant to tumour biology in both directions depending on context. This should be an oncologist's decision, not a self-directed one.

This article is educational and does not replace individual medical advice. If you take prescription medication or have a diagnosed condition, speak to your GP or pharmacist before starting Ca-AKG.

Regulatory and Quality Considerations in the UK

Ca-AKG is sold in the UK as a food supplement. As with all supplements sold in Great Britain, products cannot legally carry unauthorised health claims, and quality varies considerably between manufacturers. Because AKG salts are produced by chemical synthesis, purity and residual solvent testing genuinely matter. Look for a batch-specific certificate of analysis and prefer third-party tested supplements over brands that offer neither.

Ca-AKG vs Other Longevity Supplements

For head-to-head detail, see urolithin A vs NMN, spermidine vs NMN, NMN vs creatine, and our overview of taurine and longevity. If you want the underlying pathway explained, our NAD supplement guide covers the NAD⁺ side of the picture in full.

Does Ca-AKG Stack Well With Other Compounds?

There is no human trial of Ca-AKG in combination with NMN, resveratrol or anything else. Mechanistically they are non-overlapping — AKG works through the TCA cycle and dioxygenase cofactor availability, while NMN works through NAD⁺ — so there is no theoretical conflict, and the 2026 Aging Cell cohort found no penalty for multi-supplement use. If you are constructing a routine, our longevity stack guide and minimal supplement stack article cover how to build one without spending unnecessarily.

How to Choose a Ca-AKG Supplement in the UK

Six Things Worth Checking

1. The form is calcium AKG, not arginine or ornithine AKG. The longevity research is on Ca-AKG specifically.
2. The label states the Ca-AKG dose per capsule, not per serving of four. Cost per gram is the only fair comparison.
3. Sustained or delayed release, if you want to match the format used in the research.
4. Batch-specific certificate of analysis showing identity, purity and heavy metals.
5. Clean excipient list. Bulking agents are not dangerous but you should know what proportion of the capsule is active — see supplement fillers explained.
6. Realistic claims. Any UK product claiming to reverse ageing by a specific number of years is describing an uncontrolled study, and is doing so in a way that does not meet UK advertising standards.

For availability and pricing in the UK specifically, see our Ca-AKG supplement UK buying guide, and our breakdown of what a longevity stack actually costs in the UK and why supplements are so expensive.

Should You Take Ca-AKG? A Practical Verdict

Reasonable Candidates

• Adults over 40 who already have the fundamentals covered — resistance training, cardiovascular fitness, sleep, protein intake, blood pressure and lipids — and who are comfortable spending on an intervention that is still experimental.
• People who are already tracking epigenetic age and understand its limitations as a measure.
• Postmenopausal women interested in the bone turnover data specifically, in consultation with a clinician and counted within their total calcium intake. See also longevity supplements for women over 40.
• Men over 50 building a broader protocol — our guide for men over 50 covers sequencing.

Poor Candidates

• Anyone with kidney disease, a stone history, or existing high calcium intake.
• Anyone expecting to feel a difference. You will not.
• Anyone who would be spending money on Ca-AKG instead of, rather than alongside, exercise and diet. The effect size of Zone 2 training on healthspan dwarfs anything demonstrated for any supplement in this category.
• Anyone under 30, where the age-related decline the supplement is designed to address has not yet occurred.

The Honest Summary

Ca-AKG has the best animal healthspan data of any widely sold longevity supplement — the compression of morbidity finding in mice is genuinely notable, and it was achieved with treatment started late in life, which is the clinically relevant scenario. It also has a coherent mechanism, a long safety record and, unusually for this category, a properly designed randomised trial currently running with results expected to settle much of the debate.

What it does not have is any randomised placebo-controlled evidence of benefit in humans. The two human datasets driving consumer interest are an uncontrolled retrospective and a cross-sectional observational cohort. Both are worth taking seriously as signals. Neither is proof.

If you take it, take it as an informed experiment with a plausible mechanism and a low risk profile — not as a proven intervention.

Frequently Asked Questions

What is calcium alpha-ketoglutarate used for?

Calcium alpha-ketoglutarate is used as a longevity and healthy-ageing supplement, based on animal research showing reduced frailty and extended median lifespan in mice, and on its role as a cofactor for epigenetic enzymes. It has also been studied clinically for bone turnover in postmenopausal osteopenia and, historically, as a phosphate binder in dialysis patients. No health claims for Ca-AKG are authorised in the UK.

Does Ca-AKG actually reverse biological age?

There is no randomised controlled trial showing that Ca-AKG reverses biological age in humans. A 2021 retrospective analysis of 42 people reported an average eight-year reduction in DNA methylation age, but it had no control group. A much larger 2026 cross-sectional study of 4,260 people found delayed-release AKG had the strongest association with lower biological age among 84 supplements tested — but that is an association, not a demonstrated cause. The ABLE randomised placebo-controlled trial is designed to answer this question properly.

What is the best Ca-AKG dosage?

Most commercial products supply 1,000–3,000 mg daily. The ongoing ABLE randomised trial uses 1 g of sustained-release Ca-AKG per day, which is the most defensible dose to follow since it is the one being formally tested. The 2007 bone study used 6 g of AKG daily. Higher doses add substantial elemental calcium without human evidence of extra benefit.

How much calcium is in calcium alpha-ketoglutarate?

Roughly 20% of Ca-AKG by weight is elemental calcium, so a 1,000 mg dose provides approximately 200 mg of calcium. The NHS reference intake for adults is 700 mg a day, and it advises that supplemental intakes above 1,500 mg a day may cause stomach pain and diarrhoea. Count Ca-AKG toward your total.

Should Ca-AKG be taken with or without food?

No trial has compared the two. AKG is acidic, so taking it with food is often better tolerated. Because it delivers calcium, it is sensible to separate it by a couple of hours from iron, zinc or magnesium supplements, and from medications such as levothyroxine, bisphosphonates and tetracycline or quinolone antibiotics, which calcium can interfere with.

Are there side effects of Ca-AKG?

The most commonly reported side effects are gastrointestinal — stomach discomfort, nausea or loose stools — particularly at higher doses or in people with pre-existing stomach problems. Calcium-related constipation or bloating can also occur. The mouse lifespan study detected no significant adverse effects, and AKG holds GRAS status in the US.

Is Ca-AKG better than NMN?

They are not competing products; they target different pathways. Ca-AKG works through the TCA cycle and epigenetic cofactor availability, while NMN works by raising NAD⁺. Ca-AKG has stronger mammalian lifespan and frailty data; NMN has more human randomised trials measuring NAD⁺ levels and some functional outcomes. Neither has proven human lifespan benefit. See our NMN guide for the full comparison.

How long does Ca-AKG take to work?

There are no acute effects. Human studies have run for six to seven months and measured molecular markers rather than symptoms. If you are tracking anything, a minimum of six months is the realistic timeframe, and the only meaningful measurements are objective ones — bloods, body composition, fitness markers or an epigenetic clock.

Can you take Ca-AKG with NMN, resveratrol or other longevity supplements?

There is no evidence of interaction between them, and the 2026 Aging Cell cohort found no adverse association with multi-supplement use. The main practical consideration is the cumulative calcium and mineral load across your whole routine, and spacing minerals apart to avoid absorption competition.

Who should avoid calcium alpha-ketoglutarate?

Avoid or seek medical advice first if you have kidney disease, a history of kidney stones, hypercalcaemia, hyperparathyroidism or sarcoidosis; if you are pregnant, breastfeeding or under 18; if you have active cancer; or if you take thiazide diuretics, digoxin, bisphosphonates, levothyroxine, or tetracycline or quinolone antibiotics.

About the Medical Review

This article was medically reviewed by Dr Zeeshan Afzal (MBBS), Medical Officer at Welzo. All clinical statements have been checked against the primary literature cited in the references section. No individual clinician quotations have been used, and no claim in this article should be taken as a diagnosis or as personalised medical advice. Welzo does not sell Ca-AKG on the basis of any authorised health claim.

Disclaimer: Food supplements are not a substitute for a varied, balanced diet and a healthy lifestyle. Ca-AKG is not licensed to treat, prevent or cure any disease. If you are taking prescription medication, have a diagnosed medical condition, or are pregnant or breastfeeding, consult your GP or pharmacist before starting any new supplement.

References

1. Asadi Shahmirzadi A, Edgar D, Liao CY, et al. Alpha-Ketoglutarate, an Endogenous Metabolite, Extends Lifespan and Compresses Morbidity in Aging Mice. Cell Metabolism. 2020;32(3):447-456.e6. https://pmc.ncbi.nlm.nih.gov/articles/PMC8508957/
2. Chin RM, Fu X, Pai MY, et al. The metabolite α-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR. Nature. 2014;510:397-401. https://pmc.ncbi.nlm.nih.gov/articles/PMC4263271/
3. Su Y, Wang T, Wu N, et al. Alpha-ketoglutarate extends Drosophila lifespan by inhibiting mTOR and activating AMPK. Aging (Albany NY). 2019;11(12):4183-4197. https://pmc.ncbi.nlm.nih.gov/articles/PMC6629006/
4. Demidenko O, Barardo D, Budovskii V, et al. Rejuvant®, a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, conferred an average 8 year reduction in biological aging, after an average of 7 months of use, in the TruAge DNA methylation test. Aging (Albany NY). 2021;13(22):24485-24499. https://doi.org/10.18632/aging.203736
5. Pabis K, Wang W, Selvarajoo K, et al. Supplements and Drugs Are Associated With Biological Age in a Cohort of Exceptionally Healthy Individuals. Aging Cell. 2026;25(6):e70517. https://onlinelibrary.wiley.com/doi/full/10.1111/acel.70517
6. Filip RS, Pierzynowski SG, Lindegard B, et al. Alpha-ketoglutarate decreases serum levels of C-terminal cross-linking telopeptide of type I collagen (CTX) in postmenopausal women with osteopenia: six-month study. Int J Vitam Nutr Res. 2007;77(2):89-97. https://pubmed.ncbi.nlm.nih.gov/17896582/
7. Sandalova E, Goh J, Lim ZX, et al. Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE) — intervention study protocol. GeroScience. 2023;45(5):2897-2907. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643463/
8. Lim ZM, Chew YE, Guan L, et al. Recruitment evaluation of a gerotherapeutic randomized controlled trial testing alpha-ketoglutarate in biologically older, middle-aged adults (ABLE). Experimental Gerontology. 2025;209:112867. https://pubmed.ncbi.nlm.nih.gov/40819772/
9. Zdzisińska B, Żurek A, Kandefer-Szerszeń M. Alpha-Ketoglutarate as a Molecule with Pleiotropic Activity: Well-Known and Novel Possibilities of Therapeutic Use. Arch Immunol Ther Exp. 2017;65:21-36. https://pmc.ncbi.nlm.nih.gov/articles/PMC5274648/
10. Xu M, Zhang Q, Liu X, Lu L, Li Z. Impact of Alpha-Ketoglutarate on Skeletal Muscle Health and Exercise Performance: A Narrative Review. Nutrients. 2024;16(22):3968. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11597751/
11. Harrison AP, Pierzynowski SG. Biological effects of 2-oxoglutarate with particular emphasis on the regulation of protein, mineral and lipid absorption/metabolism, muscle performance, kidney function, bone formation and cancerogenesis, all viewed from a healthy ageing perspective. J Physiol Pharmacol. 2008;59(Suppl 1):91-106. https://pubmed.ncbi.nlm.nih.gov/18802218/
12. Tian Q, Zhao J, Yang Q, et al. Dietary alpha-ketoglutarate promotes beige adipogenesis and prevents obesity in middle-aged mice. Aging Cell. 2020;19(1):e13059. https://pmc.ncbi.nlm.nih.gov/articles/PMC6974731/
13. Riedel E, Nündel M, Hampl H. Alpha-Ketoglutarate application in hemodialysis patients improves amino acid metabolism. Nephron. 1996;74:261-265. https://pubmed.ncbi.nlm.nih.gov/8893139/
14. NHS. Vitamins and minerals — Calcium. https://www.nhs.uk/conditions/vitamins-and-minerals/calcium/
15. ClinicalTrials.gov. Evaluation of the Efficacy of Calcium α-Ketoglutarate (AKG-Ca) in Improving Human Aging. Identifier NCT07114536. https://clinicaltrials.gov/study/NCT07114536
16. Royal Osteoporosis Society. Calcium. https://theros.org.uk/information-and-support/food-and-supplements/calcium/